Baker McKenzie advised Geistlich Pharma AG (Geistlich) on its acquisition of a minority stake in TRI Dental Implants Int. AG (TRI), a fast-growing provider of digital implant solutions. This strategic partnership underscores both companies' shared commitment to advancing digital technologies in dentistry.
TRI’s groundbreaking innovation, the matrix, is the world’s first abutment-free dental implant system. It allows crowns to be attached directly to the implant, streamlining workflows and reducing costs. Supported by 10 digital apps, this system empowers clinicians with efficient, fully digital patient solutions. TRI will continue its founder-led growth, with further collaborations expected as a result of this partnership.
Baker McKenzie advised Geistlich on the legal aspects of the transaction.
The M&A team was led by Partner Alexander Fischer and included Partner Matthias Trautmann and Associate Hesam Mirzai — all from the Zurich office’s M&A Practice.
About Geistlich Pharma
Geistlich is a global leader in medical regeneration technologies headquartered in Switzerland. Employing over 800 professionals, Geistlich specializes in the development, manufacture and distribution of advanced medical devices designed for bone, cartilage and tissue regeneration.
About TRI Dental Implants
Established in 2010, TRI delivers innovative, user-friendly implant solutions from its Hünenberg (ZG) headquarters. All products are designed and manufactured in Switzerland and distributed to over 50 countries globally.
About Baker McKenzie
Complex business challenges require an integrated response across different markets, sectors and areas of law. Baker McKenzie's client solutions provide seamless advice, underpinned by deep practice and sector expertise, as well as first-rate local market knowledge. Across more than 70 offices globally, Baker McKenzie works alongside our clients to deliver solutions for a connected world.
www.bakermckenzie.com